Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fatty acid bars show promise for metabolic syndrome

NCT ID NCT07627555

Disease control Sponsor: University of Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether bars made with polyunsaturated fatty acids could improve cholesterol and fat levels in people with metabolic syndrome. 60 adults aged 40-65 with high BMI and abnormal cholesterol took part. The goal was to see if these bars could help control dyslipidemia, a key feature of metabolic syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Feb 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Metabolic syndrome patient's age 40 to 65 years with BMI (above 25 kg/m 2 ) was major part of this study. * Patients having Triglyceride levels range from mild to moderate (150 to 499 mg/dL) are included in the study. * Patients having LDL (Low density lipoprotein) range from mild (130-159 mg/dL) to moderate (160-189 mg/dL) are included in the study. * Patients having HDL (High-density lipoprotein) range from mild to moderate (60 mg/dL or higher) have been included in the study. Exclusion Criteria: * Lactating and pregnant women will not be included. * Patients who are using any kind of medicine. * Any person allergic to nuts. * Adults suffering from critical health conditions, including cancer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome cardiovascular disorder Dyslipidemias inherited lipid metabolism disorder metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemia Metabolic syndrome (METS)

Contacts and locations

Locations

  • University of Lahore

    Lahore, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.